Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Making The Business Of Drug Adherence An Easier Pill To Swallow

This article was originally published in Start Up

Executive Summary

Medication adherence is a big problem, and recent studies are bringing the actual costs and causes into sharper focus. At the same time, health care reforms such as electronic health records and prescriptions, as well as new incentives from the US government, have encouraged investors to tackle solutions to the problem. Questions remain about the impact of these reforms, but the companies profiled in this issue, HealthPrize Technologies, PillJogger, RxAnte and SentiCare, see an evolving climate in which their medication adherence technology solutions can turn into profitable businesses.

You may also be interested in...

Improved Adherence To Diabetes Drugs Can Lower Hospitalizations 13%, Study Finds

Researchers at Harvard and Express Scripts estimate that improved adherence to diabetes drugs could save nearly $5 billion annually across the U.S. health care system.

Q&A: Proteus Promotes Medication Adherence Using Ingestible Sensors

On the heels of FDA clearance for the firm's ingestible sensor technology, Proteus Digital Health Chief Medical Officer George Savage talks to “The Gray Sheet.”

Merck-Geisinger Collaboration Aims For “Pipeline” Of Treatment Adherence Tools

The first tool that will be developed is an interactive web application designed to help primary care clinicians assess and engage patients at risk for cardiometabolic syndrome.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts